Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. reported a strong turnaround for the first quarter of 2026, with revenue of $39.2 million and net income of $5.2 million, compared with a net loss a year earlier. The improvement reflects higher revenue while keeping operating expenses roughly flat.
The company ended March 31, 2026 with $61.0 million in cash, cash equivalents, and investments, which it expects to fund operations into the second quarter of 2027. Vaxart is running a BARDA‑supported Phase 2b COVID‑19 oral pill vaccine trial, with topline 12‑month safety and efficacy data from a 400‑person sentinel cohort anticipated in the second quarter of 2026 and primary data from a 5,000‑participant main cohort expected in early 2027.
Vaxart also scheduled a live stockholder fireside chat for May 8, 2026 to discuss these updates and answer investor questions.
Vaxart, Inc. has filed a prospectus supplement to sell up to $49,772,479 of common stock through an at‑the‑market (ATM) offering under a Sales Agreement with Citizens JMP Securities, LLC and B. Riley Securities, Inc. The Sales Agents may sell shares from time to time on Nasdaq, other trading venues, or in privately negotiated transactions, and are entitled to commissions up to 3% of gross sales.
The prospectus supplement bases the offering on 241,414,053 shares outstanding as of April 10, 2026 and illustrates a pro forma share count of up to 320,417,987 shares assuming sales at $0.63 per share. Net proceeds will equal gross proceeds less commissions and offering expenses; proceeds are intended for general corporate purposes including working capital, operating expenses and capital expenditures. The filing discloses a going‑concern funding need and states cash, cash equivalents and investments of $63.8 million as of December 31, 2025.
Vaxart, Inc. director James B. Breitmeyer reported receiving equity compensation in the form of common shares and stock options. He was granted 78,800 shares of Common Stock upon vesting of restricted stock units, with the underlying award vesting in three equal annual installments starting from the grant date, subject to his continued service on the Board of Directors.
He was also granted a stock option for 157,400 shares of Common Stock at an exercise price of $0.7399 per share, expiring on April 23, 2036. The option vests in three equal annual installments from the grant date, also conditioned on continued Board service. These are compensation-related awards rather than open‑market purchases or sales.
Vaxart, Inc. director James B. Breitmeyer filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing lists him as a director of Vaxart but does not report any share purchases, sales, or other transactions in the company’s securities.
Vaxart, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to provide updated Part III information on directors, executive officers, corporate governance, executive and director compensation, security ownership, related‑party transactions, and auditor fees.
The filing shows a predominantly independent board, active audit, compensation, and nominating committees, and detailed pay and equity awards for senior management and non‑employee directors. It also describes clawback, insider trading, anti‑hedging, and governance policies, plus 2025 cash and stock retainers for directors.
Vaxart, Inc. appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately, following a recommendation from the Nominating and Governance Committee. The Board determined that he meets its independence standards.
Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including leadership roles at Altay Therapeutics, Oncternal Therapeutics, Bavarian Nordic, Eli Lilly, Cadence Pharmaceuticals and others. He has led clinical programs resulting in eight FDA product approvals and multiple regulatory successes in the U.S., Europe and Japan, including vaccine-related work at Bavarian Nordic.
He will receive cash and equity compensation under Vaxart’s standard Non-Employee Director Compensation Program and has entered into the company’s standard indemnification agreement. A press release announcing his appointment was furnished as an exhibit and is not deemed filed for Exchange Act liability purposes.
Vaxart, Inc. disclosed a change in its facilities in South San Francisco. The company amended its Utah Avenue lease to add two additional suites totaling approximately 3,531 rentable square feet, beginning on May 14, 2026, with a 36‑month term.
Separately, a previously signed termination agreement will end Vaxart’s Harbor Way headquarters lease, which covers approximately 24,606 rentable square feet, effective May 15, 2026. Together, these steps shift the company’s leased footprint from its former Harbor Way headquarters toward additional space on Utah Avenue.
Vaxart, Inc. entered into a share purchase agreement with Lincoln Park Capital that allows Vaxart, at its discretion, to sell up to $25.0 million of common stock over a 24‑month period once a resale registration statement is effective.
Vaxart can direct Lincoln Park to buy up to 150,000 shares per trading day, with higher share caps at higher stock prices, subject to a $500,000 daily limit and pricing set at 97% of specified market prices. Vaxart will issue 447,067 commitment shares as consideration and the agreement limits Lincoln Park’s ownership to 4.99%, includes no warrants or participation rights, and prohibits Lincoln Park from short selling the stock.
Vaxart, Inc. filed a shelf registration to offer up to $300,000,000 of various securities and a related prospectus supplement for an at-the-market facility to sell up to $49,772,479 of common stock through Citizens JMP Securities, LLC and B. Riley Securities, Inc. under a Sales Agreement. The base prospectus allows multiple security types (common, preferred, debt, warrants, purchase contracts, units) to be offered from time to time. The prospectus states $300,000,000 aggregate capacity and notes $49,772,479 specifically allocated to the Sales Agreement; if unsold under the Sales Agreement, those shares may be sold under the base prospectus. The company reports 241,414,053 shares of common stock outstanding and a closing sale price of $0.63 on April 10, 2026. The prospectus emphasizes typical shelf qualifiers: supplements will set offering-specific terms and investors should read risk factors and incorporated reports.